The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
A systematic comparison of hepatobiliary adverse drug reactions in FDA and EMA drug labeling reveals discrepancies
Abstract
Drug labeling informs physicians and patients on the safe and effective use of medication. However, recent studies suggested discrepancies in labeling of the same drug between different regulatory agencies. Here, we evaluated the hepatic safety information in labeling for 549 medications approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Limited discrepancies were found regarding risk for hepatic adverse drug reactions (ADRs) (8.7% in hepatic ADR warnings and 21.3% in contraindication for liver disease), while caution should be exercised over drugs with inconsistencies in contraindications for liver disease and evidence for hepatotoxicity (4.9%). Most discrepancies were attributable to less-severe hepatic events and low-frequency hepatic ADR reports and had limited implication on clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Substantial differences have been identified between US (FDA) and European Medicines Agency drug labeling recommendations regarding hepatoxicity.172,173”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [173]
In the citing paper
“For example, 8.7% of the warnings for drug hepatoxicity and 21.3% of the contraindications for patients with liver disease were disparate in a recent study.173”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [173]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FDA-approved drug labeling for the study of drug-induced liver injury
Chen, M., Vijay, V., Shi, Q., Liu, Z., Fang, H., & Tong, W. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.05.007 · Cited by 406
Self-citationChen, M., Suzuki, A., Thakkar, S., Yu, K., Hu, C., & Tong, W. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.015 · Cited by 398
Self-citationRisk Factors for Idiosyncratic Drug-Induced Liver Injury
Chalasani, N., & Björnsson, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.001 · Cited by 347
Research works printed but not linked: 31
- Watson, 2009, The New Food and Drug Administration Drug Package Insert: implications for patient safety and clinical care, Anesthesia Analgesia, 108, 211, 10.1213/ane.0b013e31818c1b27 · DOI
- McMahon, 2014, The package insert: who writes it and why, what are its implications, and how well does medical school explain it?, J Psychiatric Pract, 20, 284, 10.1097/01.pra.0000452565.83039.20 · DOI
- Kashoki, 2020, A comparison of EMA and FDA decisions for new drug marketing applications 2014–2016: concordance, discordance, and why, Clin Pharmacol Ther, 107, 195, 10.1002/cpt.1565 · DOI
- Bjornsson, 2015, Discrepancies in liver disease labeling in the package inserts of commonly prescribed medications, Gastroenterology, 148, 269, 10.1053/j.gastro.2014.12.007 · DOI · Paper page
- DeMuro, 2013, Assessment of PRO label claims granted by the FDA as compared to the EMA (2006–2010), Value Health, 16, 1150, 10.1016/j.jval.2013.08.2293 · DOI
- Nieminen, 2005, Differences in product information of biopharmaceuticals in the EU and the USA: implications for product development, Eur J Pharm Biopharm, 60, 319, 10.1016/j.ejpb.2005.01.013 · doi:10.1016/j.ejpb.2005.01.013
- Ernst, 2001, Drug-related morbidity and mortality: updating the cost-of-illness model, J Am Pharm Assoc, 41, 192
- Johnson, 1997, Drug-related morbidity and mortality and the economic impact of pharmaceutical care, Am J Health-Syst Pharm, 54, 554, 10.1093/ajhp/54.5.554 · DOI · Paper page
- Lazarou, 1998, Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies, JAMA, 279, 1200, 10.1001/jama.279.15.1200 · DOI · Paper page
- Murphy, 2006, ‘Black box’ 101: how the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk, J Allergy Clin Immunol, 117, 34, 10.1016/j.jaci.2005.10.031 · DOI
- Suzuki, 2015, Comedications alter drug-induced liver injury reporting frequency: data mining in the WHO VigiBase™, Regulat Toxicol Pharmacol: RTP, 72, 481, 10.1016/j.yrtph.2015.05.004 · DOI · Paper page
- Hoyumpa, 1982, Major drug interactions: effect of liver disease, alcohol, and malnutrition, Annu Rev Med, 33, 113, 10.1146/annurev.me.33.020182.000553 · DOI
- Franz, 2013, Dose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizations, Eur J Clin Pharmacol, 69, 1565, 10.1007/s00228-013-1502-z · doi:10.1007/s00228-013-1502-z
- Frye, 2006, Liver disease selectively modulates cytochrome P450–mediated metabolism, Clin Pharmacol Ther, 80, 235, 10.1016/j.clpt.2006.05.006 · DOI · Paper page
- Chalasani, 2016, Drug-induced liver injury in patients with preexisting chronic liver disease in drug development: how to identify and manage?, Gastroenterology, 151, 1046, 10.1053/j.gastro.2016.10.010 · DOI
- Lewis, 2002, The rational use of potentially hepatotoxic medications in patients with underlying liver disease, Expert Opin Drug Saf, 1, 159, 10.1517/14740338.1.2.159 · DOI
- Russo, 2004, Are patients with elevated liver tests at increased risk of drug-induced liver injury?, Gastroenterology, 126, 1477, 10.1053/j.gastro.2004.03.030 · DOI
- Fontana, 2009, Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct, Drug Saf, 32, 55, 10.2165/00002018-200932010-00005 · DOI · Paper page
- Björnsson, 2016, Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports, Hepatology, 63, 590, 10.1002/hep.28323 · DOI · Paper page
- Liang, 2002, FDA use of the black box warning: time for reevaluation as a safety tool, J Clin Anesth, 14, 561, 10.1016/S0952-8180(02)00444-0 · DOI
- Yarrington, 2019, Impact of FDA black box warning on fluoroquinolone and alternative antibiotic use in southeastern US hospitals, Infect Control Hosp Epidemiol, 40, 1297, 10.1017/ice.2019.247 · doi:10.1017/ice.2019.247
- McCormack, 2005, Metformin’s contraindications should be contraindicated, Can Med Assoc J, 173, 502, 10.1503/cmaj.045292 · DOI
- Zaremba, 2019, Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?, J ImmunoTher Cancer, 7, 10.1186/s40425-019-0626-9 · DOI
- Björnsson, 2016, Hepatotoxicity by drugs: the most common implicated agents, Int J Mol Sci, 17, 224, 10.3390/ijms17020224 · DOI · Paper page
- Chalasani, 2015, Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study, Gastroenterology, 148, 1340, 10.1053/j.gastro.2015.03.006 · DOI · Paper page
- Suzuki, 2010, Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBaseTM, Drug Saf, 33, 503, 10.2165/11535340-000000000-00000 · DOI · Paper page
- Rockey, 2010, Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method, Hepatology, 51, 2117, 10.1002/hep.23577 · DOI · Paper page
- Hey-Hadavi, 2021, Overview of causality assessment for drug-induced liver injury (DILI) in clinical trials, Drug Saf, 44, 619, 10.1007/s40264-021-01051-5 · DOI
- Hazell, 2006, Under-reporting of adverse drug reactions: a systematic review, Drug Saf, 29, 385, 10.2165/00002018-200629050-00003 · DOI · Paper page
- Alatawi, 2017, Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS), Expert Opin Drug Saf, 16, 761, 10.1080/14740338.2017.1323867 · DOI · Paper page
- Tomlin, 2012, Methods for retrospective detection of drug safety signals and adverse events in electronic general practice records, Drug Saf, 35, 733, 10.1007/BF03261970 · DOI
Cited by
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Automatic text classification of drug-induced liver injury using document-term matrix and XGBoost
Chen, M., Wu, Y., Wingerd, B., Liu, Z., Xu, J., Thakkar, S., Pedersen, T. J., Donnelly, T., Mann, N., Tong, W., et al. (2024) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2024.1401810 · Cited by 8
Self-citation
Metadata
- Authors
- Wu, Y., Xiao, W., Tong, W., Borlak, J., & Chen, M.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2022-01
- Volume
- 27
- Issue
- 1
- Pages
- 337-346
- ISSN
- 1359-6446
- Cited by
- 12
- References
- 3
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- U.S. Food and Drug Administration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A systematic comparison of hepatobiliary adverse drug reactions in FDA and EMA drug labeling reveals discrepancies. https://app.cochat.ai/papers/10.1016/j.drudis.2021.09.009
- The paper
- Wu, Y., Xiao, W., Tong, W., Borlak, J., & Chen, M. (2022). A systematic comparison of hepatobiliary adverse drug reactions in FDA and EMA drug labeling reveals discrepancies. Drug Discovery Today. https://doi.org/10.1016/j.drudis.2021.09.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.